BirchBioMed reports breakthrough phase 2 trial results for FS2 in treating keloid scars
BirchBioMed, a Canadian clinical-stage immunology company, has unveiled promising results from a phase 2 trial of FS2, its pioneering antifibrotic therapy designed to treat keloid ... Read More
Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients
Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission's (EC) approval of Praluent (alirocumab) for a new indication. The approval enables ... Read More
Astellas, Pfizer bag Xtandi FDA approval for non-metastatic CRPC
In a significant development, Astellas Pharma and Pfizer have announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of their cancer ... Read More